COVID-19 Vaccination after Allogeneic Stem Cell Transplantation: Real Word Data on Safety and Efficacy. a Single Center Experience.

Introduction Different vaccines have been recently approved by FDA and EMA for the prevention of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, demonstrating a protection rate ranging from 60% to almost 95% in phase II/III trials. Immunocompromised patients, including those...

Descripción completa

Detalles Bibliográficos
Autores principales: Neagoie, Adela, Sommer, Charlotte, Gantner, Andrea, Wais, Verena, Schnell, Jacqueline, Simon, Hannah, Viardot, Andreas, Döhner, Hartmut, Bunjes, Donald, Sala, Elisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology. Published by Elsevier Inc. 2021
Materias:
722.Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701595/
http://dx.doi.org/10.1182/blood-2021-151061

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701595/
http://dx.doi.org/10.1182/blood-2021-151061

Ejemplares similares